Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells


A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 31 Dec 2022

Guest Editor(s)

  • Takefumi Komiya, PhD

    Medical Oncology, Parkview Cancer Institute, Fort Wayne, IN, USA.

    Website | E-mail

Special Issue Introduction

Discovery and subsequent therapeutic applications in immune checkpoints revolutionized the management of a broad range of malignancies, including non-small cell lung cancer (NSCLC). Several agents targeting PD-1/PDL1 and CTLA2 have become part of the routine practice in lung cancer management. Successful development of anti-PD-1/PDL1 axis includes their use in second-line, first-line, combination with chemotherapy, maintenance after definitive chemoradiation, adjuvant and neoadjuvant treatment with curative resection. Although we achieved regulatory approvals in these therapeutic settings, there remain numerous questions to be answered.

The goal of this special issue is to identify unsolved issues in immunotherapy that are unique and significant in NSCLC and to suggest hints to answer the questions.

We welcome submissions on the following topics but are not confined to:
● Single-agent and combination immunotherapy in metastatic NSCLC
● Neoadjuvant and adjuvant immunotherapy
● Maintenance immunotherapy after definitive local therapy
● Combination of immunotherapy and radiation
● Resistance mechanism in immunotherapy
● Role of immunotherapy in oncogene-driven NSCLC
● Management of immune-related toxicities in NSCLC

Submission Deadline

31 Dec 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Dec 2022
Contacts: Carl Zhou, Assistant Editor,

Published Articles

© 2016-2022 OAE Publishing Inc., except certain content provided by third parties